Ideation and implementation of an open science drug discovery business model – M4K Pharma

M4K Pharma was incorporated to launch an open science drug discovery program that relies on regulatory exclusivity as its primary intellectual property and commercial asset, in lieu of patents.In many cases and in key markets, using regulatory exclusivity can provide equivalent commercial protection...

Descripción completa

Detalles Bibliográficos
Autores principales: Morgan, Maxwell Robert, Roberts, Owen Gwilym, Edwards, Aled Morgan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Open Letter
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346698/
https://www.ncbi.nlm.nih.gov/pubmed/30705971
http://dx.doi.org/10.12688/wellcomeopenres.14947.1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6346698/
https://www.ncbi.nlm.nih.gov/pubmed/30705971
http://dx.doi.org/10.12688/wellcomeopenres.14947.1

Ejemplares similares